Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2

Blood

Volumn 106, Issue 10, 2005, Pages 3374-3376

  Kralovics, Robert ^b   Teo, Soon Siong ^b   Buser, Andreas S ^b   Brutsche, Martin ^b   Tiedt, Ralph ^b   Tichelli, Andre ^b   Passamonti, Francesco ^b   Pietra, Daniela ^b   Cazzola, Mario ^b   Skoda, Radek C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; JANUS KINASE 2; MOLECULAR MARKER; PROTEIN ANKRD15; STAT PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANKRD15 GENE; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOWN REGULATION; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENETIC CORRELATION; GENETIC MARKER; GRANULOCYTE; HUMAN; MAJOR CLINICAL STUDY; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 25844432737     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-05-1889     Document Type: Article

References (21)

1. Pearson TC. Evaluation of diagnostic criteria in polycythemia vera. Semin Hematol. 2001;38:21-24.
2. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol. 1999;36:9-13.
3. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
4. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science. 2002;296:1653-1655.
5. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
6. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
7. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
8. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
9. Pellagatti A, Vetrie D, Langford CF, et al. Gene expression profiling in polycythemia vera using cDNA microarray technology. Cancer Res. 2003;63:3940-3944.
10. Temerinac S, Klippel S, Strunck E, et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood. 2000;95:2569-2576.
11. Goerttler PS, Kreutz C, Donauer J, et al. Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2. Br J Haematol. 2005;129:138-150.
12. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol. 2002;30:229-236.
13. Ghilardi N, Li J, Hongo JA, et al. A novel type I cytokine receptor is expressed on monocytes, signals proliferation, and activates STAT-3 and STAT-5. J Biol Chem. 2002;277:16831-16836.
14. Kralovics R, Buser AS, Teo SS, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood. 2003;102:1869-1871.
15. Schlecht U, Demougin P, Koch R, et al. Expression profiling of mammalian male meiosis and gametogenesis identifies novel candidate genes for roles in the regulation of fertility. Mol Biol Cell. 2004;15:1031-1043.
16. Liu E, Jelinek J, Pastore YD, et al. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood. 2003;101:3294-3301.
17. Klippel S, Strunck E, Temerinac S, et al. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood. 2003;102;3569-3574.
18. Passamonti F, Pietra D, Malabarba L, et al. Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders. Br J Haematol. 2004;126:650-656.
19. Sarkar S, Roy BC, Hatano N, Aoyagi T, Gohji K, Kiyama R. A novel ankyrin repeat-containing gene (Kank) located at 9p24 is a growth suppressor of renal cell carcinoma. J Biol Chem. 2002;277:36585-36591.
20. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96:4261-4266.
21. Starr R, Willson TA, et al. A family of cytokineinducible inhibitors of signalling. Nature. 1997;387:917-921.